Acura Pharmaceuticals Supports the Stop Tampering of Prescription Pills Act of 2012
(firmenpresse) - PALATINE, IL -- (Marketwire) -- 08/02/12 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced its support for the Stop Tampering of Prescription Pills ("STOPP") Act of 2012, H.R. 6160, introduced by a bi-partisan group led by Representative William Keating (D-MA).
The Bill would amend the Federal Food, Drug and Cosmetic Act to provide a framework to define tamper-resistant technologies, thereby incentivizing the development of and market support for tamper-resistant opioid drugs. It would also serve to bring together physicians, regulators, third party payors and others concerned with the epidemic of prescription opioid abuse and misuse to promote the proper use of tamper-resistant technologies, along with other risk mitigation strategies.
"Acura has been at the forefront of developing abuse deterrent technologies to combat opioid, as well as methamphetamine misuse and abuse for the past 10 years," said Bob Jones, President and CEO, Acura Pharmaceuticals. "Clarity around the regulations as they pertain to tamper-resistant technologies would be constructive for the industry, as well as states that are considering legislation to address the prescription drug abuse epidemic."
Bill H.R. 6160 is co-sponsored by Rep. Bono Mack (R-CA), Rep. Rahall (D-WV), Rep. Rogers (R-KY), Rep. Lynch (D-MA), Rep. Towns (D-NY) and Rep. Tierney (D-MA).
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address , utilizing its proprietary AVERSION® and IMPEDE™ technologies. In June 2011, the U.S. Food and Drug Administration approved OXECTA® which incorporates the AVERSION technology. The Company has a development pipeline of additional AVERSION technology products including other opioids and its IMPEDE technology for pseudoephedrine hydrochloride products.
The trademark OXECTA® is owned by Pfizer Inc.
Contact:
212-867-1762
212-867-1762
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.08.2012 - 09:00 Uhr
Sprache: Deutsch
News-ID 1139007
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PALATINE, IL
Phone:
Kategorie:
Security
Anmerkungen:
Diese Pressemitteilung wurde bisher 238 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Acura Pharmaceuticals Supports the Stop Tampering of Prescription Pills Act of 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
Acura Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
